Abstract B73: Proof of glypican-3 (GPC3) peptide specific CTLs infiltrating into tumor tissue derived from advanced HCC patient vaccinated with GPC3 peptide.
Toshiaki Yoshikawa(Aichi Cancer Center), Tetsuya Nakatsura(Unknown), Daisuke Nobuoka(Fukuyama City Hospital), Manami Shimomura(National Cancer Center Hospital East), Kazuya Ofuji(Chiba Cancer Center), Mari Takahashi(Chiba Cancer Center), Mayuko Sakai(National Cancer Center Hospital East), Yu Sawada(Shizuoka Cancer Center)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104
Preoperative Controlling Nutritional Status (CONUT) Score for Assessment of Prognosis Following Hepatectomy for Hepatocellular Carcinoma
|World Journal of Surgery|2017|95
HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL
|International Journal of Cancer|2008|92